Imetelstat provides durable transfusion independence in heavily transfused

• Date :
• 19    
  0

Myeloma highlights from EHA 2019

• Date :
• 7    
  0

D-VTd in induction prior to and consolidation after ASCT improves PFS

• Date :
• 6    
  0

CAR T Cells for treating acute leukaemia

• Date :
• 3    
  0

Venetoclax plus obinutuzumab improves PFS and MRD-negativity

• Date :
• 1    
  0

Multiple myeloma science from EHA 2019

• Date :
• 1    
  0

Novel immunotherapy 5F9+rituximab well tolerated with rapid and durable responses

• Date :
• 1    
  0

Inhibition of NADK strongly inhibits T-ALL cells from growing

• Date :
• 1    
  0

Intervention for AML patients with MRD can result in improved survival

• Date :
• 1    
  0

Venetoclax with bortezomib and dexamethasone shows good response

• Date :
• 0    
  0

Most pregnancies in CML patients resulted in normal childbirth

• Date :
• 0    
  0

Acalabrutinib monotherapy shows significant benefit

• Date :
• 0    
  0

Selinexor plus cytarabine and idarubicin in patients

• Date :
• 0    
  0

Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients

• Date :
• 0    
  0

MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma

• Date :
• 0    
  0

Blinatumomab for relapsed/refractory Burkitt's lymphoma

• Date :
• 0    
  0

PET after 2 cycles of ABVD in patients with early-stage favourable hodgkin lymphoma

• Date :
• 0    
  0

CLL14: Can we treat CLL without chemotherapy, venetoclax plus obinutuzumab

• Date :
• 0    
  0

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL

• Date :
• 0    
  0

Echelon-1 study 3 year update: Frontline brentuximab vedotin with chemotherapy

• Date :
• 0    
  0

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy

• Date :
• 0    
  0

Comment on fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities

• Date :
• 0    
  0

Comment on pregnancy outcomes in patients with chronic myeloid leukaemia

• Date :
• 0    
  0

Safety and efficacy of escalating doses of the hu5f9-g4 with rituximab in patients

• Date :
• 0    
  0

Chemotherapy-free strategies in treating leukaemia

• Date :
• 0    
  0

ADMIRAL trial results: Gilteritinib versus salvage chemotherapy

• Date :
• 0    
  0

AlloHCT conditioning intensity in AML in complete remission with residual disease

• Date :
• 0    
  0

ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine

• Date :
• 0    
  0

CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML

• Date :
• 0    
  0

Combination of pegcrisantaspase and venetoclax in acute myeloid leukaemia

• Date :
• 0    
  0

Chemoimmunotherapy or BTK inhibition for patients with CLL

• Date :
• 0    
  0

Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for B-ALL

• Date :
• 0    
  0

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone

• Date :
• 0    
  0

HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab

• Date :
• 0    
  0

Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL

• Date :
• 0    
  0

Targeted treatment of AML using T cell recruiting antibody constructs

• Date :
• 0    
  0

RESONATE-2: Five-year follow up of CLL patients receiving ibrutinib as first-line treatment

• Date :
• 0    
  0

The changing landscape of AML

• Date :
• 0    
  0

Using bioinformatics and genomics to treat AML

• Date :
• 0    
  0

9ème Journée Nationale Maladies Rares Immuno-Hématologiques - MaRIH 2023

• Date :
• 3380    
  6

International Society on Thrombosis and Haemostasis congress - ISTH 2023

• Date :
• 4963    
  0

The European Hematology Association - EHA 2023

• Date :
• 8092    
  0

MDS - 17th International Congress on Myelodysplastic Syndromes

• Date :
• 12637    
  0

43e congrès annuel de la Société Française d’Hématologie - SFH 2023

• Date :
• 9346    
  7